Toward a better definition of hematopoietic progenitors suitable for B cell differentiation

PLoS One. 2020 Dec 15;15(12):e0243769. doi: 10.1371/journal.pone.0243769. eCollection 2020.

Abstract

The success of inducing human pluripotent stem cells (hIPSC) offers new opportunities for cell-based therapy. Since B cells exert roles as effector and as regulator of immune responses in different clinical settings, we were interested in generating B cells from hIPSC. We differentiated human embryonic stem cells (hESC) and hIPSC into B cells onto OP9 and MS-5 stromal cells successively. We overcame issues in generating CD34+CD43+ hematopoietic progenitors with appropriate cytokine conditions and emphasized the difficulties to generate proper hematopoietic progenitors. We highlight CD31intCD45int phenotype as a possible marker of hematopoietic progenitors suitable for B cell differentiation. Defining precisely proper lymphoid progenitors will improve the study of their lineage commitment and the signals needed during the in vitro process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / metabolism
  • B-Lymphocytes / cytology*
  • Cell Differentiation*
  • Embryonic Stem Cells / cytology
  • Gene Expression Regulation
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Phenotype

Substances

  • Antigens, CD

Grants and funding

This work was supported in the context of the Centaure project (RP10083) and the LabEX IGO thanks to French government financial support managed by the National Research Agency via the "Investment into the Future" program (ANR-11- LABX-0016-01). The ANR project BIKET (ANR-17-CE17-0008) also financially support this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.